- Latest customer is a behavioral health care provider, operating four facilities and an outpatient program, with SOBRsafe’s technology being initially installed in one facility, with greater footprint possible
- SOBRsafe’s next-generation transdermal technology detects and instantly reports the presence of alcohol as emitted through the user’s skin. No breath, blood, or urine sample is required
- SOBRsafe’s technology is geared toward behavioral health, judicial and consumer markets, and for licensing and integration
SOBRsafe (NASDAQ: SOBR), a provider of transdermal alcohol detection technology that provides advanced screening and monitoring solutions for the behavioral health and justice industries, recently announced that the company’s game-changing products are gaining momentum – with a fourth behavioral health care provider signing with SOBRsafe. The behavioral health care provider (name withheld for patient privacy considerations) operates four facilities and an outpatient program. The provider will initially install SOBRcheck(TM) in one facility for point-of-care screening and is evaluating the technology for expansion into its remaining facilities. The customer also plans to evaluate the wearable SOBRsure(TM) band for continuous monitoring in an outpatient scenario (https://ibn.fm/tjpHD).
“This customer is consistent with our approach to the behavioral health market – sign providers with multiple uses for our technology, prove its efficacy, and expand within the account,” SOBRsafe chairman and CEO Dave Gandini said. “We are proud of our progress within behavioral health, and we believe that these foundational customer commitments could accelerate industry adoption.”
SOBRsafe’s next-generation transdermal technology detects and instantly reports the presence of alcohol as emitted through the user’s skin. No breath, blood, or urine sample is required. SOBRsafe believes its technology is a more efficient, hygienic and connected replacement for traditional breathalyzers in frontline, preventative applications.
SOBRsafe’s full detection product line includes:
SOBRsafe(TM) – a scalable, patent-pending platform for non-invasive alcohol detection, real-time reporting, and historical data aggregation. The company’s mission is to improve behavioral outcomes and help save lives. Its vision is to become the standard for alcohol screening and monitoring.
SOBRcheck(TM) – the company’s stationary identification and alcohol monitoring product, which provides a quick, specific point-of-care test for the presence of alcohol. Using transdermal (touch-based) technology, SOBRcheck verifies user identity and determines the absence or presence of alcohol – with immediate results delivered securely to aid in the efficient management of an existing substance abuse policy.
SOBRsure(TM) – SOBRsure is a transdermal, alcohol-detecting wearable that provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. SOBRsure provides administrators app-based alcohol detection alerts, pinpoint location tracking, and band removal notifications.
SOBRsafe’s technology is commercially available for point-of-care, wearable use, and licensing or integration. SOBRsafe’s technology offers a powerful backend data platform that is humane and passive – geared toward behavioral health, justice, and consumer markets.
Mr. Gandini also recently participated in the virtual Lytham Partners 2024 Investor Select Conference held on February 1, 2024. His participation in the online event included a fireside chat and one-on-one meetings with investors. Anyone interested in the live replay of the event can watch it on the company’s website (https://ibn.fm/1wmGy).
For more information, visit the company’s website at www.SOBRsafe.com.
NOTE TO INVESTORS: The latest news and updates relating to SOBR are available in the company’s newsroom at https://ibn.fm/SOBR